ULBP2 and breast cancer: Whatever the mechanism involved, the association of these NK-activating ligands with shorter time to relapse and survival suggests that BC patients expressing high levels of BAT3, CD58, or ULBP2 may be favorable candidates for NK-cell based therapy.